CCDC 717077: Experimental Crystal Structure Determination
Leo Alig(Roche (Switzerland)), P. C. Waldmeier(Novartis (Switzerland)), A. Mayweg(Roche (Switzerland)), Wolfgang Guba(Roche (Switzerland)), Anne Bourson(Roche (Switzerland)), M. Rogers-Evans, Agnès Bénardeau(Roche (Switzerland)), Matthias Nettekoven(Roche (Switzerland)), G. Schneider, Robert Narquizian(Roche (Switzerland)), Stefan Hildbrand(Roche (Switzerland)), Dagmar Kube(Roche (Switzerland)), Pascale David‐Pierson(Roche (Switzerland)), Jean‐Marc Plancher(Roche (Switzerland)), Stephan Röver(Roche (Switzerland)), Konrad Bleicher(Roche (Switzerland)), Werner Neidhart(Roche (Switzerland)), S. Taylor(Pharmaron (United Kingdom)), Jochem Alsenz(Roche (Switzerland)), Thomas Lübbers(Roche (Switzerland)), C. Rocha, Stefanie Bendels(Roche (Switzerland)), Mirjana Andjelković(Roche (Switzerland))
Cited by 0
Related Papers
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
|Science|1995|1.8k
Fluorine in Medicinal Chemistry
|ChemBioChem|2004|1.5k
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568
Specific γ‐hydroxybutyrate‐binding sites but loss of pharmacological effects of γ‐hydroxybutyrate in GABA<sub>B(1)</sub>‐deficient mice
|European Journal of Neuroscience|2003|184